Richard Narido

Richard leads the Financial and Administrative operations for our Company.  He recently served as the Chief Financial Officer of Lucira Health (Lucira) until Pfizer Inc. acquired Lucira in 2023. At Lucira Health, Rich successfully scaled the Company’s operations from a recently FDA-approved product to a Company with over $150 million of annualized global sales and a global supply chain footprint. From 2023 until Rich joined Amprion, he consulted a range of companies from early stage to publicly traded companies such as NRx Pharmaceuticals, Inc. where Rich served as their Chief Financial Officer and the Company’s principal financial officer and principal accounting officer.  From July 2018 to March 2021, Rich served in various roles at Assembly Biosciences, Inc., including most recently as Executive Director, Finance, Controllership, and Treasury.

 

From June 2014 to June 2018, Rich served in various roles at Bio-Rad Laboratories, Inc., including as Americas Head of Finance, Global Commercial Operations. Prior to June 2018, Rich held various finance roles, including Global Head Finance Reporting and Accounting for Novartis Vaccines and Diagnostics Division, and several industry-related positions, including Business Unit Controller for McKesson Corporation. Mr. Narido also serves as a board member on the Arthritis National Research Foundation’s board of directors.

 

Rich started his career with PricewaterhouseCoopers’ Financial Audit and Assurance practice. He holds a Bachelor of Science degree from the University of San Francisco and a Master of Science degree from the Pepperdine Graziadio Business School.